Eli Lilly boasts a wide range of products that serve a vast number of therapeutic areas. LLY focuses primarily on ...
12h
Morning Market Brief: Breakthrough Biology Meets Scalable Platforms as Innovators Surge into Focus
Alumis is firmly in focus after announcing positive topline results from two Phase 3 trials (ONWARD1 and ONWARD2) evaluating envudeucitinib , its next-generation oral TYK2 inhibitor, in ...
The future of urban green space might be written in code, according to research in the International Journal of ...
We’re seeing major investors put serious money into AI startups, which is fueling a wave of new ideas and technologies. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback